EligibleTrials

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

Recruiting · NCT07633639 · Interventional (participants receive a specific treatment) · Lead sponsor: China-Japan Friendship Hospital

View the official record on ClinicalTrials.gov →
Obesity

Interventions studied

LSG groupLSG-Mazdutide groupLSG-Semaglutide groupLSG-Tirzepatide group

What this trial is about

Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.

Who can take part

Age range
18 Years to 60 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.